Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05556096 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
A Phase 3 study of Generalized Myasthenia Gravis, sponsored by Alexion Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 261
- Enrollment target
- 20
- Study locations
NCT05556096: Active Phase 3 study of Generalized Myasthenia Gravis, sponsored by Alexion Pharmaceuticals.
NCT05556096 is a Phase 3 study of Generalized Myasthenia Gravis that is active but no longer recruiting, run by Alexion Pharmaceuticals. The registered enrollment target is 261 participants, above the 121-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (116% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05556096, a Phase 3 study of Generalized Myasthenia Gravis, is active but no longer recruiting, sponsored by Alexion Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 261 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
Conditions Studied
Interventions
- COMBINATION_PRODUCT Placebo
- COMBINATION_PRODUCT ALXN1720
Study Locations (20)
Florida
- Research Site - Bradenton
- Research Site - Maitland
- Research Site - Tampa
Georgia
- Research Site - Augusta
- Research Site - Gainesville
- Research Site - Savannah
New York
- Research Site - Patchogue
- Research Site - Rochester
- Research Site - Syracuse
Michigan
- Research Site - Detroit
- Research Site - East Lansing
California
- Research Site - Orange
Colorado
- Research Site - Fort Collins
District of Columbia
- Research Site - Washington D.C.
Illinois
- Research Site - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2022-11-21 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 3 |
What the registry record for NCT05556096 still lists
NCT05556096 is an interventional study that assigns participants to a tested intervention. The registered 261 participants enrollment target is mid-sized for trials with a published cap, above the 121-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (116% higher).
The record links to 1 condition, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05556096 names 20 study sites across 13 states, led by Florida, Georgia, New York.
Frequently Asked Questions
What is clinical trial NCT05556096 about?
NCT05556096 is a clinical study titled "Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis". The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
What is the current status of trial NCT05556096?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 261 participants. The study started on 2022-11-21. Estimated completion is 2027-08-31.
What conditions does trial NCT05556096 study?
This clinical trial studies the following conditions: Generalized Myasthenia Gravis.
What interventions are being tested in trial NCT05556096?
The interventions under investigation include: Placebo (COMBINATION_PRODUCT), ALXN1720 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05556096?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05556096 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05556096's enrollment target sits among peer trials
261 4th of 26 higher than 23 of 26 other Generalized Myasthenia Gravis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Generalized Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
RECRUITING · Phase 3
-
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05124912 · 261 participants · NA
REMASTer: REcurrent Brain Metastases After SRS Trial
- NCT06559891 · 261 participants · NA
THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
- NCT03713268 · 262 participants
Intraoperative OCT Guidance of Intraocular Surgery II
- NCT06074380 · 262 participants · Phase 4
Non Inferiority Trial Investigating Surfactants Administered Via MIST
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI